Suven Life Sciences, a Hyderabad-based drug company, jumped 4.91 per cent to close at Rs 34.20 after it secured product patents in Russia and Australia for two of its new chemical entities (NCEs).

<tr><td><p class='TableClas'></p><P class='TableClas'><DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>These patents are valid until 2023 and will be useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like Alzheimer's disease, Parkinson's disease, schizophrenia and Huntington's disease. The total quantity traded today was 1.69 lakh shares.</P></p><p class='TableClas'></p></table>


Patents give booster dose to Suven Life

DALAL STREET SPIKES

More From This Section

Idea shares fall after Q3 earnings disappoint

BofA-Merrill raises Indiabulls to 'buy', stock gains

Suzlon stocks jump 17% on CDR approval

Maruti Suzuki rallies as Q3 profit beats analyst's estimates

Explore News